Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $344.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 4.16% year-over-year to $344.9 million; the TTM figure through Mar 2026 stood at $344.9 million (up 4.16% YoY), while the FY2025 annual figure was $345.0 million, up 3.55% from the prior year.
• Total Non-Current Liabilities was $344.9 million for Q1 2026 at Syndax Pharmaceuticals, roughly flat from $345.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $345.0 million in Q4 2025 to a low of $2000.0 in Q3 2024.
• Historically, Total Non-Current Liabilities has averaged $119.9 million across 5 years, with a median of $1.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities sank 99.77% in 2024, then surged 16108650.0% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $722000.0 in 2022, then slipped by 18.56% to $588000.0 in 2023, then jumped by 56556.97% to $333.1 million in 2024, then advanced by 3.55% to $345.0 million in 2025, then slipped by 0.03% to $344.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $344.9 million (Q1 2026), $345.0 million (Q4 2025), and $322.2 million (Q3 2025), per Business Quant data.